Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of GC012F injection in relapsed/refractory multiple myeloma
CTR20232951Phase 2Active
- Sponsor
- Gracell Biotechnologies
- Start
- Dec 2023
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of GC012 in multiple myeloma (MM), sponsored by Gracell Biotechnologies. Started Dec 2023; status: active.
02
Drugs
GC012
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on CTR20232951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232951.